PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcmedgenoBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Medical Genomics
 
BMC Med Genomics. 2008; 1: 24.
Published online Jun 11, 2008. doi:  10.1186/1755-8794-1-24
PMCID: PMC2442111
Genotyping panel for assessing response to cancer chemotherapy
Zunyan Dai,corresponding author#1,2 Audrey C Papp,#1 Danxin Wang,#1 Heather Hampel,3 and Wolfgang Sadeecorresponding author1
1Program in Pharmacogenomics, Department of Pharmacology, Comprehensive Cancer Center, College of Medicine and Public Health, The Ohio State University, 5072 Graves Hall, 333 West 10th Avenue, Columbus, OH 43210-1239, USA
2Department of Pathology, College of Medicine and Public Health, The Ohio State University, 680 Ackerman Road, Columbus, Ohio 43202, USA
3Division of Human Genetics, College of Medicine and Public Health, The Ohio State University, 2050 Kenny Road, 8th floor tower, Columbus, OH 43221, USA
corresponding authorCorresponding author.
#Contributed equally.
Zunyan Dai: dai.15/at/osu.edu; Audrey C Papp: papp.2/at/osu.edu; Danxin Wang: Wang.808/at/osu.edu; Heather Hampel: Heather.Hampel/at/osumc.edu; Wolfgang Sadee: Wolfgang.Sadee/at/osumc.edu
Received October 31, 2007; Accepted June 11, 2008.
Abstract
Background
Variants in numerous genes are thought to affect the success or failure of cancer chemotherapy. Interindividual variability can result from genes involved in drug metabolism and transport, drug targets (receptors, enzymes, etc), and proteins relevant to cell survival (e.g., cell cycle, DNA repair, and apoptosis). The purpose of the current study is to establish a flexible, cost-effective, high-throughput genotyping platform for candidate genes involved in chemoresistance and -sensitivity, and treatment outcomes.
Methods
We have adopted SNPlex for genotyping 432 single nucleotide polymorphisms (SNPs) in 160 candidate genes implicated in response to anticancer chemotherapy.
Results
The genotyping panels were applied to 39 patients with chronic lymphocytic leukemia undergoing flavopiridol chemotherapy, and 90 patients with colorectal cancer. 408 SNPs (94%) produced successful genotyping results. Additional genotyping methods were established for polymorphisms undetectable by SNPlex, including multiplexed SNaPshot for CYP2D6 SNPs, and PCR amplification with fluorescently labeled primers for the UGT1A1 promoter (TA)nTAA repeat polymorphism.
Conclusion
This genotyping panel is useful for supporting clinical anticancer drug trials to identify polymorphisms that contribute to interindividual variability in drug response. Availability of population genetic data across multiple studies has the potential to yield genetic biomarkers for optimizing anticancer therapy.
Articles from BMC Medical Genomics are provided here courtesy of
BioMed Central